Three leading U.S. lawmakers have raised serious concerns regarding the Food and Drug Administration's (FDA) foreign drug inspection programme in India and China. In a letter dated June 21, House Energy and Commerce Committee Chair Cathy McMorris Rodgers, Health Subcommittee Chair Brett Guthrie, and Oversight and Investigations Subcommittee Chair Morgan Griffith questioned the discrepancies in FDA inspection outcomes in these countries.
The lawmakers' letter to FDA Commissioner Robert Califf followed an analysis of the FDA's inspection results from January 2014 to April 2024. Their findings pointed to significant inconsistencies in inspection outcomes. “The results of this analysis were surprising, revealing tremendous variation in inspection outcomes. Some FDA inspectors found compliance issues during all or almost all of their inspections. Other inspectors rarely reported finding a single compliance issue”, the lawmakers wrote.
For instance, two inspectors reported zero compliance issues across 24 inspections in India. Similarly, another inspector identified no compliance issues in 20 out of 23 inspections (85%) in China, yet found issues in nearly half of domestic inspections during the same period. These anomalies are striking, especially considering the documented challenges in quality control and adherence to good manufacturing practices in these countries.
In contrast, the lawmakers highlighted the rigorous findings of 16 other FDA inspectors, who identified compliance issues during every inspection out of more than 325 inspections in India. They also pointed to three inspectors with a reputation for thoroughness who reported finding compliance issues during inspections in China at a rate of only 6.7% to 11.4%, and in India at a rate of 0% to 9.5%. These disparities raise concerns about the consistency and reliability of the FDA's inspection processes abroad.
The letter underscores the need for a thorough review of the FDA's foreign drug inspection protocols. "Such large variations in inspection outcomes are troubling, and they merit further investigation", the lawmakers stated. They questioned whether these differences indicate a lack of uniformity in the skills, thoroughness, and competence of FDA inspectors, or if they reflect deeper institutional issues within the FDA's foreign inspection programme.
The lawmakers urged Commissioner Califf to provide more information about the FDA’s inspection methodologies and oversight mechanisms in India and China. They requested a detailed explanation of how the FDA ensures the integrity and consistency of its inspections globally and how it addresses potential gaps in the training and performance of its inspectors.
Given the critical role of the FDA in ensuring the safety and efficacy of pharmaceuticals, the lawmakers stressed the importance of robust and reliable inspection protocols, especially in countries that are significant suppliers of generic drugs to the U.S. market. They called for immediate action to rectify any deficiencies and to restore confidence in the FDA's ability to oversee the global pharmaceutical supply chain effectively.
The call for transparency and improvement in the FDA's inspection programme comes amid growing scrutiny of international drug manufacturing practices and their impact on drug safety in the United States.